Literature DB >> 31404925

Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.

James J Chamberlain1, Kacie Doyle-Delgado1, Lacie Peterson2, Neil Skolnik3.   

Abstract

Description: The American Diabetes Association (ADA) annually updates its Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.
Methods: The ADA Professional Practice Committee comprises physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, pharmacists, and public health experts. To develop the 2019 standards, the committee continuously searched MEDLINE through November 2018 to consider and review studies, particularly high-quality trials including persons with diabetes, for potential incorporation into recommendations. It also solicited feedback from the larger clinical community. Recommendations: This synopsis focuses on selected guidance relating to use of diabetes technology in adults with diabetes. Recommendations address self-monitoring of blood glucose, continuous glucose monitors, and automated insulin delivery systems.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31404925     DOI: 10.7326/M19-1638

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  Diabetes Technologies: We Are All in This Together.

Authors:  Sean M Oser; Tamara K Oser
Journal:  Clin Diabetes       Date:  2020-04

2.  The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) - Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes.

Authors:  Moritsugu Kimura; Masao Toyoda; Nobumichi Saito; Makiko Takahashi; Konomi Isozumi; Eri Kato; Daiji Kawanami; Masafumi Fukagawa
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-25       Impact factor: 3.249

3.  Remote patient monitoring sustains reductions of hemoglobin A1c in underserved patients to 12 months.

Authors:  Elizabeth B Kirkland; Justin Marsden; Jingwen Zhang; Samuel O Schumann; John Bian; Patrick Mauldin; William P Moran
Journal:  Prim Care Diabetes       Date:  2021-01-25       Impact factor: 2.567

Review 4.  SGLT2i: beyond the glucose-lowering effect.

Authors:  Lihua Ni; Cheng Yuan; Guopeng Chen; Changjiang Zhang; Xiaoyan Wu
Journal:  Cardiovasc Diabetol       Date:  2020-06-26       Impact factor: 9.951

5.  Salvia miltiorrhiza improves type 2 diabetes: A protocol for systematic review and meta-analysis.

Authors:  Ying Guo; Jianfeng Sun; Renyan Zhang; Peng Yang; Sanyin Zhang; Zhipeng Wu
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

6.  Proinflammatory cytokines predict the incidence of diabetic peripheral neuropathy over 5 years in Chinese type 2 diabetes patients: A prospective cohort study.

Authors:  Hangping Zheng; Wanwan Sun; Qi Zhang; Yuanpin Zhang; Lijin Ji; Xiaoxia Liu; Xiaoming Zhu; Hongying Ye; Qian Xiong; Yiming Li; Bin Lu; Shuo Zhang
Journal:  EClinicalMedicine       Date:  2020-12-23

7.  Integrating diabetes technologies with team-based primary care for type 2 diabetes: A pilot trial.

Authors:  Matthew J O'Brien; John J Stephen; Kristine L Norton; Thomas P Meehan; Deneen Vojta; Ronald T Ackermann
Journal:  Prim Care Diabetes       Date:  2021-07-21       Impact factor: 2.567

8.  Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease.

Authors:  Ming-Hsien Wu; Chia-Ni Lin; Daniel Tsun-Yee Chiu; Szu-Tah Chen
Journal:  Diagnostics (Basel)       Date:  2020-04-09

9.  The Alteration of Carnitine Metabolism in Second Trimester in GDM and a Nomogram for Predicting Macrosomia.

Authors:  Man Sun; Baihui Zhao; Sainan He; Ruopeng Weng; Binqiao Wang; Yunping Ding; Xinwen Huang; Qiong Luo
Journal:  J Diabetes Res       Date:  2020-08-11       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.